lobbying_activities: 3343830

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3343830	3df0c399-ae01-430e-b0f7-eb302f64c329	Q1	AARP	1694	AARP	2025	first_quarter	PHA	H. Con. Res. 14/S. Con. Res. 7, the Budget Reconciliation Resolution S. 1096, the Preserving Access to Affordable Generics and Biosimilars Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1040, the Drug Competition Enhancement Act. H.R. 9070/S. 1041, the Affordable Prescriptions for Patients Act. S. 1097, the Interagency Patent Coordination and Improvement Act of 2025. No bill number. Discussed pharmacy benefit managers. S. 527, Prescription Pricing for the People Act of 2025. S. 526, the Pharmacy Benefit Manager (PBM) Transparency Act of 2025. S. 229, the Drug-Price Transparency for Consumers (DTC) Act of 2025. No bill number. Discussed Medicare Part D. No bill number. Discussed cap on out-of-pocket prescription drug costs. No bill number. Discussed the Medicare Prescription Payment Plan. No bill number. Discussed the Medicare drug price negotiation program.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office		6630000	0	0	2025-04-18T08:49:09-04:00